top of page
Henning Mann
Admin
More actions
Profile
Join date: May 23, 2025
Posts (5)
Nov 18, 2025 ∙ 3 min
From Worms to Workstreams: How Ora Biomedical Is Scaling AI Driven Longevity Discovery
Mini StartUp Review & Example for Fractional BD Opportunity By Henning Mann, PhD | HM.BioConsulting 3–5 minute read Download the File “Longevity research is evolving. AI and automation are accelerating drug discovery. In this space Ora Biomedical is one to watch.” Background: Aging as a Modifiable Endpoint Aging is the single greatest risk factor for most chronic diseases, yet for decades, drug discovery pipelines have focused on treating symptoms rather than addressing upstream biological...
1
0
Nov 4, 2025 ∙ 17 min
Organ-on-Chip in 2025: In the Spotlight After the NIH, FDA, and GAO Push
Download the article: A conversation between Elizabeth (Lizzy) Crist, Business Development Manager & Technical Lead (USA), AIM Biotech and Henning Mann, PhD, Founder & CEO, HM.BioConsulting, former Sen. Dir. Applied Science, Nortis Inc., Executive Intro With the FDA, NIH, and GAO each advancing the shift toward human-based preclinical models , Organ-on-Chip (OoC) and broader Microphysiological Systems (MPS) technologies have been moved into the spotlight and given unprecedented key...
8
0
Sep 30, 2025 ∙ 6 min
Capital Discipline in 2025: How Emerging Biotechs Can Thrive in a Constrained Funding Market
Review Opinion: Henning Mann, PhD, HM.BioConsulting LLC Download PDF: The more conversations we have with clients and prospects, the more...
9
0
bottom of page